Objective To investigate the efficacy of different doses of propranolol in the treatment of infantile hemangiomas (IHs). Methods From January 2012 to December 2016, patients aged from 1 to 6 months with infantile hemangiomas were enrolled onto this study. Follow the randomized double-blind control principle, Patients were randomly divided into 3 groups according to different doses of propranolol :group 1 (1mg/kg/d), group 2 (2mg/kg/d) and group 3 (3mg/kg/d). Results Efficacy of the three groups respectively were 48.9% and 71.1% and 77.8%. There had statistically significant between the three groups. There had statistically significant between group1 and group2(P=0.031).There had statistically significant between group1 and group3(P=0.004). There had no statistically significant between group2 and group3(P=0.468). There had statistically significant between the three groups by incidence of adverse effects(P=0.001).There had no statistically significant between group1 and group2(P=0.071).There had statistically significant between group1 and group3(P=0.000).There had statistically significant between group2 and group3(P=0.031).Conclusion Oral propranolol was an effective and safty option for infantile hemangiomas.With the dose increase,and the efficiency gradually increase ,but the adverse effects increased by the way too. Choosing the dose of group2 by 2mg/kg/d for the treatment Infantile Hemangiomas was effective and could reduce the incidence of adverse effects.%目的:评估不同剂量的普萘洛尔治疗婴幼儿血管瘤的临床疗效.方法:2012年1月-2016年12月,根据血管瘤诊断标准纳入1~6月龄的患儿,遵循随机双盲对照原则,将患儿分为治疗1组1mg/kg/d、治疗2组2mg/kg/d及治疗3组3mg/kg/d进行临床观察治疗.结果:治疗1组总有效率为48.9%,治疗2组总有效率为71.1%,治疗3组总有效率77.8%,三组有效率比较有统计学意义(P=0.010).治疗1组与治疗2组间比较有统计学意义(P=0.031),治疗1组与治疗3组间比较有统计学意义(P=0.004),治疗2组与治疗3组间比较无统计学意义(P=0.468).三组不良反应发生率比较有统计学意义(P=0.001),治疗1组与治疗2组间比较无统计学意义(P=0.071),治疗1组与治疗2组间比较有统计学意义(P=0.000),治疗2组与治疗3组间比较有统计学意义(P=0.031).结论:口服普萘洛尔治疗婴幼儿血管瘤安全、有效,随着剂量加大,有效率逐步提高的同时相关不良反应率也在上升,选用治疗2组(即2mg/kg/d组)治疗婴幼儿血管瘤能在保证治疗效果的情况下减少不良反应的发生.
展开▼
